» Articles » PMID: 34249740

Abscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Jul 12
PMID 34249740
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Although abscopal tumor regression remains a rare phenomenon, interest in exploiting how radiation stimulates the immune system to induce systemic abscopal response is increasing. Here, we tested the hypothesis that tumor immunogenicity determined the ability of radiotherapy to induce abscopal effects. We established highly (MC-38 and E.G7-OVA) or poorly (LL/2 and B16-F10) immunogenic tumor models in this study and treated them with sham radiation, a single dose of 15 Gy, or three fractions of 5 Gy on three consecutive days. Alterations in the tumor microenvironment after radiation were examined by flow cytometry and RNA sequencing. Our results demonstrated the positive correlation between tumor immunogenicity and the abscopal effect of radiotherapy. The single dose of 15 Gy radiation was an effective regimen for inducing abscopal effects in highly immunogenic tumors. Local radiation reshaped the tumor microenvironment of irradiated and non-irradiated distant tumors by increasing CD8 T-cell infiltration and reducing suppressive immune cell accumulation. However, radiation alone was insufficient to elicit abscopal effects in poorly immunogenic tumors. No significant alterations were detected in the non-irradiated distant tumor microenvironment after radiation of poorly immunogenic tumors. In addition, tumor immunogenic subtypes were associated with the radiological response and clinical outcome of patients receiving radiotherapy. These findings indicated that tumor immunogenicity was the dominant characteristic that could predict the abscopal effect of radiotherapy. Our study provides an in-depth understanding of the immunological mechanisms involved in abscopal effects and highlights the impact of tumor heterogeneity on the therapeutic efficacy of radiotherapy and their combination with immunotherapy in clinical trials.

Citing Articles

Physical parameters and biological factors affect the abscopal effect of combining radiotherapy with immunotherapy: an update on preclinical works.

Ren W, Wen J, Guo G, Gu W, Zhang S, Liu C Front Public Health. 2025; 12:1517147.

PMID: 39949344 PMC: 11822297. DOI: 10.3389/fpubh.2024.1517147.


Enabling immune checkpoint blockade efficacy in T-lymphopenia by restoring CD8 T cell dynamics with IL-7 cytokine therapy.

Kang Y, Choi D, Moon D, Lee K, Oh Y, Yang J Front Immunol. 2025; 15:1477171.

PMID: 39763661 PMC: 11701376. DOI: 10.3389/fimmu.2024.1477171.


Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.

Amit U, Uslu U, Verginadis I, Kim M, Oliaei Motlagh S, Diffenderfer E Proc Natl Acad Sci U S A. 2024; 121(31):e2403002121.

PMID: 39047033 PMC: 11294999. DOI: 10.1073/pnas.2403002121.


Nomogram model of survival prediction for nasopharyngeal carcinoma with lung metastasis: developed from the SEER database and validated externally.

Xiao Z, Li K, Su F, Yang X, Zou H, Qu S Front Oncol. 2024; 14:1351578.

PMID: 38567156 PMC: 10985206. DOI: 10.3389/fonc.2024.1351578.


PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice.

Frijlink E, Bosma D, Bosma D, Busselaar J, Battaglia T, Staal M J Clin Invest. 2024; 134(6).

PMID: 38349740 PMC: 10940086. DOI: 10.1172/JCI171154.


References
1.
Kim K, Kim H, Kim J, Jung H, Sun J, Ahn J . Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. Nat Commun. 2020; 11(1):951. PMC: 7031381. DOI: 10.1038/s41467-020-14562-z. View

2.
Zhou J, Donaubauer A, Frey B, Becker I, Rutzner S, Eckstein M . Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. J Immunother Cancer. 2021; 9(2). PMC: 7888377. DOI: 10.1136/jitc-2020-001845. View

3.
Wang W, Chapman N, Zhang B, Li M, Fan M, Laribee R . Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-κB Contributes to UV Radiation-Induced Immune Suppression. Cancer Res. 2019; 79(11):2909-2922. PMC: 6548650. DOI: 10.1158/0008-5472.CAN-18-3134. View

4.
Dewan M, Galloway A, Kawashima N, Dewyngaert J, Babb J, Formenti S . Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009; 15(17):5379-88. PMC: 2746048. DOI: 10.1158/1078-0432.CCR-09-0265. View

5.
Yarchoan M, Hopkins A, Jaffee E . Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017; 377(25):2500-2501. PMC: 6549688. DOI: 10.1056/NEJMc1713444. View